BioSight
Companies
Olema Pharmaceuticals, Inc. logo

OLMA

NASDAQSAN FRANCISCO, CA
Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals is a clinical-stage biotech company developing small-molecule drugs targeting cancer. The company's lead candidate, palazestrant, is in Phase 1/2 and Phase 3 clinical trials, while OP-3136 is in Phase 1 development. Olema is pursuing regulatory approvals and plans to commercialize these drug candidates if they prove successful.

Price history not yet available for OLMA.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar